Adenosine receptors and Huntington's disease: Implications for pathogenesis and therapeutics

Lancet Neurology

Volumn 2, Issue 6, 2003, Pages 366-374

  Blum, David ^a   Hourez, Raphaël ^a,b   Galas, Marie Christine ^a   Popoli, Patrizia ^c   Schiffmann, Serge N ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 6 ETHYL 4 PROPYL 2 PHENYL 3 PYRIDINECARBOXYLIC ACID 5 THIOCARBOXYLIC ACID 5 ETHYL 3 PROPYL ESTER; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR; BACLOFEN; DEXTROMETHORPHAN; HUNTINGTIN; ISTRADEFYLLINE; KETAMINE; LAMOTRIGINE; MSX 3; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; PRESYNAPTIC RECEPTOR; RILUZOLE; UNCLASSIFIED DRUG; ZW 241385;

BRAIN NERVE CELL; CELL NUCLEUS INCLUSION BODY; CORPUS STRIATUM; DATA ANALYSIS; DRUG EFFECT; GENE MUTATION; GENETIC ANALYSIS; GENETIC MODEL; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; MITOCHONDRION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; OUTCOMES RESEARCH; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; REVIEW; SYNAPSE;

ADENOSINE; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTON DISEASE; MITOCHONDRIAL DISEASES; MODELS, MOLECULAR; MODELS, NEUROLOGICAL; MUTATION; NEURAL NETWORKS (COMPUTER); NEUROPROTECTIVE AGENTS; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE;

EID: 0038231381     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(03)00411-3     Document Type: Review

References (140)

1. Harper P.S. Huntington's Disease. 2nd edn:1996;WB Saunder, London.
2. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., Young A.B. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA. 85:1988;5733-5737.
3. Heinsen H., Strik M., Bauer M., et al. Cortical and striatal neurone number in Huntington's disease. Acta Neuropathol (Berl). 88:1994;320-333.
4. Hedreen J.C., Peyser C.E., Folstein S.E., Ross C.A. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci Lett. 133:1991;257-261.
5. Gusella J.F., Wexler N.S., Conneally P.M., et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature. 306:1983;234-238.
6. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 72:1993;971-983.
7. Davies S.W., Turmaine M., Cozens B.A., et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 90:1997;537-548.
8. Menalled L.B., Chesselet M.F. Mouse models of Huntington's disease. Trends Pharmacol Sci. 23:2002;32-39.
9. Mangiarini L., Sathasivam K., Seller M., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87:1996;493-506.
10. DiFiglia M., Sapp E., Chase K.O., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 277:1997;1990-1993.
11. de Almeida L.P., Ross C.A., Zala D., Aebischer P., Deglon N. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci. 22:2002;3473-3483.
12. Deglon N. Lentiviral vectors-mediated gene transfer as a new strategy to model Huntington's disease. 13th Nectar meeting, Amsterdam, Netherlands, 2002.
13. Saudou F., Finkbeiner S., Devys D., Greenberg M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 95:1998;55-66.
14. Gutekunst C.A., Li S.H., Yi H., et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci. 19:1999;2522-2534.
15. Goldberg Y.P., Nicholson D.W., Rasper D.M., et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet. 13:1996;442-449.
16. Gafni J., Ellerby L.M. Calpain activation in Huntington's disease. J Neurosci. 22:2002;4842-4849.
17. Hodgson J.G., Agopyan N., Gutekunst C.A., et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 23:1999;181-192.
18. Steffan J.S., Kazantsev A., Spasic-Boskovic O., et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA. 97:2000;6763-6768.
19. Boutell J.M., Thomas P., Neal J.W., et al. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum Mol Genet. 8:1999;1647-1655.
20. Nucifora F.C. Jr, Sasaki M., Peters M.F., et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science. 291:2001;2423-2428.
21. Dunah A.W., Jeong H., Griffin A., et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science. 296:2002;2238-2243.
22. Cha J.H., Frey A.S., Alsdorf S.A., et al. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos Trans R Soc Lond B Biol Sci. 354:1999;981-989.
23. Cha J.H. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 23:2000;387-392.
24. Dragatsis I., Levine M.S., Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet. 26:2000;300-306.
25. Zuccato C., Ciammola A., Rigamonti D., et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 293:2001;493-498.
26. Rigamonti D., Bauer J.H., De Fraja C., et al. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci. 20:2000;3705-3713.
27. Gervais F.G., Singaraja R., Xanthoudakis S., et al. Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat Cell Biol. 4:2002;95-105.
28. Cattaneo E., Rigamonti D., Goffredo D., Zuccato C., Squitieri F., Sipione S. Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci. 24:2001;182-188.
29. Brouillet E., Conde F., Beal M.F., Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol. 59:1999;427-468.
30. Beal M.F. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci. 23:2000;298-304.
31. Arzberger T., Krampfl K., Leimgruber S., Weindl A. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease: an in situ hybridization study. J Neuropathol Exp Neurol. 56:1997;440-454.
32. Levine M.S., Klapstein G.J., Koppel A., et al. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res. 58:1999;515-532.
33. Zeron M.M., Hansson O., Chen N., et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron. 33:2002;849-860.
34. Behrens P.F., Franz P., Woodman B., Lindenberg K.S., Landwehrmeyer G.B. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain. 125:2002;1908-1922.
35. Sawa A., Wiegand G.W., Cooper J., et al. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med. 5:1999;1194-1198.
36. Panov A.V., Gutekunst C.A., Leavitt B.R., et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci. 5:2002;731-736.
37. Alexi T., Borlongan C.V., Faull R.L., et al. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Prog Neurobiol. 60:2000;409-470.
38. Blum D., Gall D., Cuvelier L., Schiffmann S.N. Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. Neuroreport. 12:2001;1769-1772.
39. El Massioui N., Ouary S., Cheruel F., Hantraye P., Brouillet E. Perseverative behavior underlying attentional set-shifting deficits in rats chronically treated with the neurotoxin 3-nitropropionic acid. Exp Neurol. 172:2001;172-181.
40. Blum D., Galas M.C., Gall D., Cuvelier L., Schiffmann S.N. Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. Neurobiol Dis. 10:2002;410-426.
41. Rowland L.P. Merritt's neurology. 10th edn:2000;Lippincott Williams and Wilkins, Philadelphia.
42. Denovan-Wright E.M., Devarajan S., Dursun S.M., Robertson H.A. Maintained improvement with minocycline of a patient with advanced Huntington's disease. J Psychopharmacol. 16:2002;393-394.
43. de Almeida L.P., Zala D., Aebischer P., Deglon N. Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol Dis. 8:2001;433-446.
44. Mittoux V., Joseph J.M., Conde F., et al. Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. Hum Gene Ther. 11:2000;1177-1187.
45. Humbert S., Bryson E.A., Cordelieres F.P., et al. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves huntingtin phosphorylation by Akt. Dev Cell. 2:2002;831-837.
46. Nakao N., Itakura T. Fetal tissue transplants in animal models of Huntington's disease: the effects on damaged neuronal circuitry and behavioral deficits. Prog Neurobiol. 61:2000;313-338.
47. Bachoud-Levi A.C., Remy P., Nguyen J.P., et al. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet. 356:2000;1975-1979.
48. Ralevic V., Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 50:1998;413-492.
49. Dunwiddie T.V., Masino S.A. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci. 24:2001;31-55.
50. Fredholm B.B., Ijzerman A.P., Jacobson K.A., Klotz K.N., Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 53:2001;527-552.
51. Fredholm B.B., Battig K., Holmen J., Nehlig A., Zvartau E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 51:1999;83-133.
52. Fredholm B.B. Are methylxanthine effects due to antagonism of endogenous adenosine? Trends Pharmacol Sci. 1:1980;129-132.
53. Delaney S.M., Geiger J.D. Brain regional levels of adenosine and adenosine nucleotides in rats killed by high-energy focused microwave irradiation. J Neurosci Methods. 64:1996;151-156.
54. Dunwiddie T.V., Diao L. Extracellular adenosine concentrations in hippocampal brain slices and the tonic inhibitory modulation of evoked excitatory responses. J Pharmacol Exp Ther. 268:1994;537-545.
55. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol. 362:2000;299-309.
56. Dunwiddie T.V., Diao L., Proctor W.R. Adenine nucleotides undergo rapid, quantitative conversion to adenosine in the extracellular space in rat hippocampus. J Neurosci. 17:1997;7673-7682.
57. Delaney S.M., Shepel P.N., Geiger J.D. Levels of endogenous adenosine in rat striatum: I, regulation by ionotropic glutamate receptors, nitric oxide and free radicals. J Pharmacol Exp Ther. 285:1998;561-567.
58. Manzoni O.J., Manabe T., Nicoll R.A. Release of adenosine by activation of NMDA receptors in the hippocampus. Science. 265:1994;2098-2101.
59. Rudolphi K.A., Schubert P., Parkinson F.E., Fredholm B.B. Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol Sci. 13:1992;439-445.
60. Latini S., Bordoni F., Pedata F., Corradetti R. Extracellular adenosine concentrations during in vitro ischaemia in rat hippocampal slices. Br J Pharmacol. 127:1999;729-739.
61. Schiffmann S.N., Libert F., Vassart G., Dumont J.E., Vanderhaeghen J.J. A cloned G protein-coupled protein with a distribution restricted to striatal medium-sized neurons: possible relationship with D1 dopamine receptor. Brain Res. 519:1990;333-337.
62. Reppert S.M., Weaver D.R., Stehle J.H., Rivkees S.A. Molecular cloning and characterization of a rat A1-adenosine receptor that is widely expressed in brain and spinal cord. Mol Endocrinol. 5:1991;1037-1048.
63. Rivkees S.A., Price S.L., Zhou F.C. Immunohistochemical detection of A1 adenosine receptors in rat brain with emphasis on localization in the hippocampal formation, cerebral cortex, cerebellum, and basal ganglia. Brain Res. 677:1995;193-203.
64. Ferre S., O'Connor W.T., Svenningsson P., et al. Dopamine D1 receptor-mediated facilitation of GABAergic neurotransmission in the rat strioentopenduncular pathway and its modulation by adenosine A1 receptor-mediated mechanisms. Suppl Eur J Neurosci. 8:1996;1545-1553.
65. Fredholm B.B., Dunwiddie T.V. How does adenosine inhibit transmitter release? Trends Pharmacol Sci. 9:1988;130-134.
66. Schiffmann S.N., Jacobs O., Vanderhaeghen J.J. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem. 57:1991;1062-1067.
67. Fink J.S., Weaver D.R., Rivkees S.A., et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res. 14:1992;186-195.
68. Schiffmann S.N., Vanderhaeghen J.J. Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J Neurosci. 13:1993;1080-1087.
69. 2A antagonists. J Neurosci (in press).
70. Hettinger B.D., Lee A., Linden J., Rosin D.L. Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol. 431:2001;331-446.
71. Popoli P., Pintor A., Domenici M.R., et al. Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J Neurosci. 22:2002;1967-1975.
72. Ledent C., Vaugeois J.M., Schiffmann S.N., et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature. 388:1997;674-678.
73. Johansson B., Halldner L., Dunwiddie T.V., et al. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci USA. 98:2001;9407-9412.
74. Ferre S., Herrera-Marschitz M., Grabowska-Anden M., Ungerstedt U., Casas M., Anden N.E. Postsynaptic dopamine/adenosine interaction: I. Adenosine analogues inhibit dopamine D2-mediated behaviour in short-term reserpinized mice. Eur J Pharmacol. 192:1991;25-30.
75. Svenningsson P., Nomikos G.G., Ongini E., Fredholm B.B. Antagonism of adenosine A2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens. Neuroscience. 79:1997;753-764.
76. Kase H. New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia. Biosci Biotechnol Biochem. 65:2001;1447-1457.
77. Jakel R.J., Maragos W.F. Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci. 23:2000;239-245.
78. de Mendonca A., Sebastiao A.M., Ribeiro J.A. Adenosine: does it have a neuroprotective role after all? Brain Res Brain Res Rev. 33:2000;258-274.
79. Fredholm B.B. Adenosine and neuroprotection. Int Rev Neurobiol. 40:1997;259-280.
80. Daval J.L., Nicolas F. Opposite effects of cyclohexyladenosine and theophylline on hypoxic damage in cultured neurons. Neurosci Lett. 175:1994;114-116.
81. Lynch J.J. III, Alexander K.M., Jarvis M.F., Kowaluk E.A. Inhibition of adenosine kinase during oxygen-glucose deprivation in rat cortical neuronal cultures. Neurosci Lett. 252:1998;207-210.
82. Barth A., Newell D.W., Nguyen L.B., et al. Neurotoxicity in organotypic hippocampal slices mediated by adenosine analogues and nitric oxide. Brain Res. 762:1997;79-88.
83. Von Lubitz D.K., Dambrosia J.M., Kempski O., Redmond D.J. Cyclohexyl adenosine protects against neuronal death following ischemia in the CA1 region of gerbil hippocampus. Stroke. 19:1988;1133-1139.
84. Von Lubitz D.K., Marangos P.J. Cerebral ischemia in gerbils: postischemic administration of cyclohexyl adenosine and 8-sulfophenyl- theophylline. J Mol Neurosci. 2:1990;53-59.
85. Von Lubitz D.K., Lin R.C., Melman N., Ji X.D., Carter M.F., Jacobson K.A. Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia. Eur J Pharmacol. 256:1994;161-167.
86. Jacobson K.A., Von Lubitz D.K., Daly J.W., Fredholm B.B. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol Sci. 17:1996;108-113.
87. Boissard C.G., Lindner M.D., Gribkoff V.K. Hypoxia produces cell death in the rat hippocampus in the presence of an A1 adenosine receptor antagonist: an anatomical and behavioral study. Neuroscience. 48:1992;807-812.
88. Phillis J.W. The effects of selective A1 and A2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res. 705:1995;79-84.
89. Fowler J.C. Adenosine antagonists delay hypoxia-induced depression of neuronal activity in hippocampal brain slice. Brain Res. 490:1989;378-384.
90. Fowler J.C. Adenosine antagonists alter the synaptic response to in vitro ischemia in the rat hippocampus. Brain Res. 509:1990;331-334.
91. Schubert P., Rudolphi K.A., Fredholm B.B., Nakamura Y. Modulation of nerve and glial function by adenosine: role in the development of ischemic damage. Int J Biochem. 26:1994;1227-1236.
92. White P.J., Rose'Meyer R.B., Hope W. Functional characterization of adenosine receptors in the nucleus tractus solitarius mediating hypotensive responses in the rat. Br J Pharmacol. 117:1996;305-308.
93. Williams M. Purinergic drugs: opportunities in the 1990s. Drug Res Dev. 28:1993;438-441.
94. Von Lubitz D.K., Lin R.C., Paul I.A., et al. Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils. Eur J Pharmacol. 316:1996;171-179.
95. Bischofberger N., Jacobson K.A., Von Lubitz D.K. Adenosine A1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders. Ann N Y Acad Sci. 825:1997;23-29.
96. Blum D., Gall D., Galas M.C., d'Alcantara P., Bantubungi K., Schiffmann S.N. The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. J Neurosci. 22:2002;9122-9133.
97. Zuchora B., Turski W.A., Wielosz M., Urbanska E.M. Protective effect of adenosine receptor agonists in a new model of epilepsy-seizures evoked by mitochondrial toxin, 3-nitropropionic acid, in mice. Neurosci Lett. 305:2001;91-94.
98. de Mendonca A., Sebastiao A.M., Ribeiro J.A. Inhibition of NMDA receptor-mediated currents in isolated rat hippocampal neurones by adenosine A1 receptor activation. Neuroreport. 6:1995;1097-1100.
99. d'Alcantara P., Ledent C., Swillens S., Schiffmann S.N. Inactivation of adenosine A2A receptor impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission. Neuroscience. 107:2001;455-464.
100. Flagmeyer I., Haas H.L., Stevens D.R. Adenosine A1 receptor-mediated depression of corticostriatal and thalamostriatal glutamatergic synaptic potentials in vitro. Brain Res. 778:1997;178-185.
101. Guyot M.C., Palfi S., Stutzmann J.M., Maziere M., Hantraye P., Brouillet E. Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats. Neuroscience. 81:1997;141-149.
102. Beal M.F., Brouillet E., Jenkins B.G., et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci. 13:1993;4181-4192.
103. Jones P.A., Smith R.A., Stone T.W. Protection against hippocampal kainate excitotoxicity by intracerebral administration of an adenosine A2A receptor antagonist. Brain Res. 800:1998;328-335.
104. Chen J.F., Huang Z., Ma J., et al. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci. 19:1999;9192-9200.
105. Monopoli A., Lozza G., Forlani A., Mattavelli A., Ongini E. Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport. 9:1998;3955-3959.
106. Schwarzschild M.A., Chen J.F., Ascherio A. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology. 58:2002;1154-1160.
107. Svenningsson P., Le Moine C., Fisone G., Fredholm B.B. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol. 59:1999;355-396.
108. Fenu S., Pinna A., Ongini E., Morelli M. Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol. 321:1997;143-147.
109. Blum D., Torch S., Lambeng N., et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol. 65:2001;135-172.
110. Grondin R., Bedard P.J., Hadj T.A., Gregoire L., Mori A., Kase H. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology. 52:1999;1673-1677.
111. Koga K., Kurokawa M., Ochi M., Nakamura J., Kuwana Y. Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur J Pharmacol. 408:2000;249-255.
112. Chen J.F., Xu K., Petzer J.P., et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci. 21:2001;RC143.
113. Ikeda K., Kurokawa M., Aoyama S., Kuwana Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J Neurochem. 80:2002;262-270.
114. Glass M., Dragunow M., Faull R.L. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience. 97:2000;505-519.
115. Mitchell I.J., Cooper A.J., Griffiths M.R. The selective vulnerability of striatopallidal neurons. Prog Neurobiol. 59:1999;691-719.
116. Albin R.L., Reiner A., Anderson K.D., et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann Neurol. 31:1992;425-430.
117. Richfield E.K., Maguire-Zeiss K.A., Vonkeman H.E., Voorn P. Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients. Ann Neurol. 38:1995;852-861.
118. Menalled L., Zanjani H., MacKenzie L., et al. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp Neurol. 162:2000;328-342.
119. Varani K., Rigamonti D., Sipione S., et al. Aberrant amplification of A(2A) receptor signaling in striatal cells expressing mutant huntingtin. FASEB J. 15:2001;1245-1247.
120. Bordelon Y.M., Chesselet M.F. Early effects of intrastriatal injections of quinolinic acid on microtubule-associated protein-2 and neuropeptides in rat basal ganglia. Neuroscience. 93:1999;843-853.
121. Pranzatelli M.R., Albin R.L., Cohen B.H. Acute dyskinesias in young asthmatics treated with theophylline. Pediatr Neurol. 7:1991;216-219.
122. Stuart A.M., Worley L.M., Spillane J. Choreiform movements observed in an 8-year-old child following use of an oral theophylline preparation. Clin Pediatr (Phila). 31:1992;692-694.
123. Richter A., Hamann M., Bartling C. CGS 21680 exerts marked antidystonic effects in a genetic model of paroxysmal dyskinesia. Eur J Pharmacol. 404:2000;299-302.
124. Calabresi P., Gubellini P., Picconi B., et al. Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J Neurosci. 21:2001;5110-5120.
125. Popoli P., Betto P., Reggio R., Ricciarello G. Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur J Pharmacol. 287:1995;215-217.
126. +-evoked glutamate release in vivo in young and aged rats. Neuroreport. 10:1999;687-691.
127. Corsi C., Melani A., Bianchi L., Pedata F. Striatal A2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats. Neuroreport. 11:2000;2591-2595.
128. Pintor A., Quarta D., Pezzola A., Reggio R., Popoli P. SCH 58261 (an adenosine A(2A) receptor antagonist) reduces, only at low doses, K(+)-evoked glutamate release in the striatum. Eur J Pharmacol. 421:2001;177-180.
129. Ohta A., Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 414:2001;916-920.
130. Mayne M., Fotheringham J., Yan H.J., et al. Adenosine A2A receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage. Ann Neurol. 49:2001;727-735.
131. Sapp E., Kegel K.B., Aronin N., et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol. 60:2001;161-172.
132. Pedata F., Corsi C., Melani A., Bordoni F., Latini S. Adenosine extracellular brain concentrations and role of A2A receptors in ischemia. Ann N Y Acad Sci. 939:2001;74-84.
133. Brodie M.S., Lee K., Fredholm B.B., Stahle L., Dunwiddie T.V. Central versus peripheral mediation of responses to adenosine receptor agonists: evidence against a central mode of action. Brain Res. 415:1987;323-330.
134. Wilbur S.L., Marchlinski F.E. Adenosine as an antiarrhythmic agent. Am J Cardiol. 79:1997;30-37.
135. Merkel L.A., Hawkins E.D., Colussi D.J., et al. Cardiovascular and antilipolytic effects of the adenosine agonist GR79236. Pharmacology. 51:1995;224-236.
136. Anderson R., Sheehan M.J., Strong P. Characterization of the adenosine receptors mediating hypothermia in the conscious mouse. Br J Pharmacol. 113:1994;1386-1390.
137. Knutsen L.J., Lau J., Petersen H., et al. N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects. J Med Chem. 42:1999;3463-3477.
138. Knutsen L.J., Weiss S.M. KW-6002 (Kyowa Hakko Kogyo). Curr Opin Investig Drugs. 2:2001;668-673.
139. Kanda T., Jackson M.J., Smith L.A., et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol. 43:1998;507-513.
140. Richardson P.J., Kase H., Jenner P.G. Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci. 18:1997;338-344.